Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + erlotinib + metformin in advanced pancreatic cancer
2009-017716-32Phase 2Active
- Sponsor
- Academic Medical Center
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic cancer (PC) comparing Gemcitabine + erlotinib + metformin with Gemcitabine + erlotinib + placebo (2 arms). Primary endpoint: survival after 6 months. Started Jan 2010; status: active.
02
Drugs
metformin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2009-017716-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017716-32.